CRDF earnings date and last-quarter result: last quarter miss, P/E -1.28. Updated 2026-07-23.
Cardiff Oncology (CRDF) Research Hub
Cardiff Oncology (CRDF) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.8043 USD (-11.35%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.28, market cap 0.06B. This hub links to the full technical, earnings and options research available for CRDF.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.8043 USD (-11.35%) |
| 52-week range | 0.7566 USD – 1.6 USD |
| Trend regime | Range |
| 14-day RSI | 20.6 (Oversold) |
| Trailing P/E | -1.28 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
Available research for CRDF
Covered Call on CRDF: how it works, illustrative setup around the real 0.8043 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRDF: how it works, illustrative setup around the real 0.8043 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRDF: how it works, illustrative setup around the real 0.8043 USD price, max profit/loss, breakeven and when to use it. Educational.
CRDF technical analysis: range, last 0.8043 USD, RSI 20.6, 52w range 0.7566 USD–1.6 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CRDF in?
Cardiff Oncology (CRDF) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CRDF in an uptrend or downtrend?
As of 2026-10-26, CRDF is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRDF's trailing P/E ratio?
CRDF's trailing P/E is -1.28, with a market cap of 0.06B. See the earnings research page for full valuation detail.